ADA 2026 Preview  – May 18 2026

Friday, June 5

• (10:30 am – 12:30 pm): Welcome to the 2026 ADA Scientific Sessions: Keynote address by Dr. Jay Bhattacharya & ‘Pathway to Stop Diabetes’ symposium. We’re eager to attend the opening session of the 86th Annual Scientific Sessions, which will feature remarks from the ADA’s own CEO Mr. Charles Henderson and a keynote address from Dr. Bhattacharya, who serves as the Director of the NIH. Dr. Bhattacharya will speak on key issues shaping healthcare and research and introduce to the “Pathway to Stop Diabetes” symposium. Emerging leaders, including Dr. Marie-France Hivert (Harvard University), Dr. Chelsea Hepler (University of Michigan), and Dr. Tinashe Chikowore (Harvard University), will also share brief presentations in this opening session on their respective efforts for diabetes prevention and treatment. We will have “walking trains” from W!LD’s opening event that will recognize Yale Medicine’s very esteemed Dr. Jennifer Sherr. RSVP here to what is sure to be a spectacular early morning with W!LD! (…drop in any time between 7:30 am and 10:30 am.)
• (12:45 pm – 1:45 pm): Debate – Continuous ketone monitoring for the masses: Risky or rewarding? In this timely debate, Dr. Jennifer Sherr herself (Yale University) and Dr. Jeremy Pettus (UCSD) will take opposing positions on the potential adoption and use cases of continuous ketone monitoring (CKM). We expect Dr. Sherr to advocate for CKM as a next step in metabolic monitoring, highlighting its potential to improve glycemic safety, particularly in detecting and providing real-time insights on the development and resolution of early diabetic ketoacidosis (DKA). On the opposing side, Dr. Pettus will argue against the broad use of CKM, focusing on concerns around cost and practicality. While we don’t imagine for a moment that Dr. Pettus is actually against ketone monitoring, we salute him for accepting a challenging position, just like his colleague, UCSD’s Dr. Steve Edelman has done many times in the past. With rebuttals and audience discussion built into the format, this session should offer a very fascinating and critical look at ketone monitoring and kidney health.
• (12:45 pm – 1:45 pm): Human studies in obesity treatment: Emerging therapeutic options and strategies for decision-making. In this session, four speakers will highlight emerging pharmacological therapies and treatment strategies in obesity management. Dr. Julio Rosenstock (University of Texas Southwestern Medical Center) will present results from the ACCESS trial (n=82) evaluating the effects of GLP-1 RA aleniglipron in people living with overweight and obesity. Dr. Andrea Foppiani (University of Milan) will discuss how the rate of early weight loss can inform escalation strategies in obesity treatment, offering a framework for individualized therapy adjustment. Dr. Junfang Xu (Huadong Medicine) will cover phase 2 data on HDM1005’s efficacy and safety in obese patients without diabetes. Dr. Nikolaj Bak (Novo Nordisk) will conclude with insight into the effects of CagriSema on appetite and functional brain activity. We’re excited to learn how new therapies may be efficacious across multiple physiological contexts.
• (2:00 pm – 3:30 pm): Preventing type 1 diabetes. In this oral presentation session, six speakers will all offer updates on T1D cures. Dr. Kenneth Brayman (University of Virginia) will kick off the session with a potential novel, tolerance-restoring therapeutic for T1D – the Fcµ fragment of IgM. Later, we’ll hear from Ms. Sarah Holly (Children’s National Hospital) on operationalizing T1D screening and monitoring. Dr. Stephen Gitelman (UCSF) will present results from the TEPLI-REAL study (n=110). As background, TEPLI-REAL is a real-world, retrospective study evaluating metabolic outcomes in patients treated with Tzield (teplizumab). Next, Dr. Eric Sandhurst (SAB Bio) will offer an update on SAB-142, which is currently evaluated in the 52-week phase 2b SAFEGUARD study (n=159). Finally, we’re eager to hear from Dr. Anna Lam (University of Alberta, Canada), who will share findings on residual beta cell function, which was found to confer glycemic benefit beyond AID in new-onset T1D.
• (2:00 pm – 3:30 pm): Session #1: What's new with insulin delivery systems? This set of oral presentations will showcase the latest clinical advancements and real-world challenges with AID systems. Dr. Tugce Akcan (Stanford Medicine) opens with an ADA President’s Select Abstract on evaluating AID use in hospitalized patients with advanced kidney disease (1063-OR). Next, Dr. Alice Adenis (Diabeloop) will examine how physical activity and baseline metabolic state influence glycemic outcomes (1064-OR), while Mr. Ahtsham Zafar (University College Dublin, Ireland) will present results on how premeal insulin-on-board and meal size affect postprandial excursions (1065-OR). Dr. Eri Takagi (Juntendo University Graduate School of Medicine, Japan) will then present data suggesting that menstrual cycle-related insulin requirements may shift independently of symptoms in individuals using AID (1066-OR). We are particularly interested in multicenter trial data, including Dr. Carol Levy (Mount Sinai Diabetes Center), who will present results on the twiist AID system in insulin-treated T2D (1067-OR), and Dr. Gregory Forlenza (University of Colorado), who will share findings from the STRIVE trial evaluating a next-generation Omnipod algorithm (1068-OR). Together, these presentations should highlight both the increasing complexity of AID systems and the real-world challenges that continue to impact glycemic management.
• (3:45 pm – 5:15 pm): Amylin as a novel diabetes and obesity therapy. We’re eager to attend this Friday afternoon symposium, chaired by Dr. Timothy Garvey (University of Alabama at Birmingham). The session will feature a rich discussion and the latest updates on amylin as a therapy for diabetes and obesity. Prof. Thomas Lutz (Universität Zürich, Switzerland) will discuss the neuropharmacology and biological actions of amylin. Building on this understanding, Prof. Carel le Roux (St. Vincent’s University Hospital and University College Dublin, Ireland) will update us on the current clinical trial data for long-acting amylin analogs. We imagine this discussion will include: (i) Novo Nordisk’s cagrilintide, which conferred 12% weight loss at 68 weeks; (ii) Lilly’s eloralintide, which achieved weight loss up to 20% at 48 weeks; and (iii) Roche and Zealand’s petrelintide, which conferred 11% weight loss at 42 weeks. Lastly, Dr. Garvey will take the podium to evaluate where these long-acting amylin analogs might fit in the pharmacotherapeutic landscape for metabolic disease.
• (3:45 pm – 5:15 pm): Obesity Year in Review: Major Advances and Discoveries. Alongside our exploration of Amylin, we’ll dive into this sure-to-be compelling deep dive into obesity chaired by Dr. Ellen Schur (University of Washington). First, Weill Cornell’s Dr. Louis Aronne will explore clinical improvements to obesity management over the year – we imagine Dr. Aronne will include a discussion of the Lancet’s latest obesity framework published in January 2025, which focuses on clinical diagnostic criteria rather than BMI alone. Next, Dr. Elizabeth Parks (University of Missouri) will discuss translational advances in the past year and Dr. Julio Ayala (Vanderbilt University) will discuss developments in basic science. At ECO 2026, we explored the neurobiology behind eating and its implications for obesity, including fast-acting neurotransmitters and lingering neuropeptides. We look forward to seeing how Drs. Park and Ayala integrate our understanding of biological circuits into obesity care.
• (5:30 pm – 6:30 pm): Dual agonism in type 1 diabetes: Unveiling efficacy and safety of adjunct therapy with CT-868 (GLP-1/GIP RA) in adults with T1D — Phase 1 and 2 results. We’re excited to attend this Friday evening session, which will discuss Roche’s CT-868, a dual GLP-1/GIP RA for T1D. As background, a 16-week phase 2 trial (n=111) was completed in July 2025, with full results expected in this meeting. Roche also announced in 4Q25 that the phase 3 trial of CT-868 will launch this year for people with T1D and BMI ≥25 kg/m². Dr. Richard Pratley (Advent Health) will deliver new results from a phase 1, proof-of-mechanism study in T1D. Dr. Klara Klein (University of North Carolina at Chapel Hill) will then discuss phase 2 trial design, baseline characteristics, and key glycemic endpoints. Finally, Dr. Jeremy Pettus (UCSD) will conclude with key secondary endpoints, safety and tolerability profile findings, and clinical interpretation of the phase 2 trial. We look forward to the study results, as there are currently no incretin-based therapies approved for T1D. We are also curious to learn if there are mechanistic reasons for Roche targeting T1D, instead of T2D or the broader obesity population, for this candidate.

Saturday, June 6

• (8:00 am – 9:30 am): The ADA’s Standards of Care in diabetes: 2026 updates. In this annual feature, six speakers will review updates to the 2026 ADA Standards of Care. Dr. Elizabeth Ann Beverly (Ohio University) will kick off with a deep dive into “Facilitating Positive Health Behaviors and Well-Being to Improve Health Outcomes.” Dr. Alissa Segal (Massachusetts College of Pharmacy & Health Sciences) will follow, remarking on changes to “Pharmacological Approaches to Glycemic Management.” Dr. Anne Peters (University of Southern California) and Dr. Dave Dixon (Virginia Commonwealth University) will next discuss diabetes technology and “Cardiovascular Disease and Risk Management,” respectively. Lastly, Dr. Emily Szmuilowicz (Northwestern University) will cover updates to “Management of Diabetes in Pregnancy,” and Dr. Lori Laffel (Joslin Diabetes Center) will review the “Diabetes in Children and Adolescents” chapter of the guidelines.
• (8:00 am – 9:30 am): The VESPER-1, -2 and -3 trials of MET-097 (PF-08653944), an ultra-long-acting GLP-1 receptor agonist for weight management. We’re eager to attend this Saturday morning review of the VESPER-1 (n=239), VESPER-2 (n=133), and VESPER-3 (n=250) trials of MET-097 (an ultra-long-acting GLP-1 RA), which features a stellar lineup of speakers. First, Prof. Naveed Sattar (University of Glasgow, UK) will give an overview of the growing global obesity and overweight crisis. Dr. Louis Aronne (Weill Cornell Medical College) will follow with the design of MET-097, which aims to be a scalable treatment for weight management. Dr. John Buse (University of North Carolina Chapel Hill) will then present results of the VESPER-2 trial of MET-097 for adults with overweight or obesity and diabetes, while Dr. Ildiko Lingvay (University of Texas Southwestern) will share results from the VESPER-1 open-label extension, which assessed long-term treatment of MET-097. Last, but not least, Dr. Ania Jastreboff (Yale University) will present the primary outcomes of the phase 2 VESPER-3 trial, which evaluated monthly MET-097 dosing for weight management. We look forward to hearing the trial results and learning how MET-097 might distinguish itself from other incretin-based treatments.
• (1:30 pm – 3:00 pm): Unlocking the next frontier in treatment of obesity and type 2 diabetes with retatrutide: A triple agonist activating GIP, GLP-1, and Glucagon Receptors (TRANSCEND-T2D-1 and TRIUMPH-1 results). This long-awaited symposium will share phase 3 results from Lilly’s retatrutide (triple GIP/GLP-1/glucagon RA), which is characterized as the “next frontier” in obesity and T2D treatment. Dr. Ildiko Lingvay (UT Southwestern) will open with a forward-looking presentation on what’s upcoming for clinical management of T2D and obesity. Afterward, Dr. Jonathan Campbell (Duke University) will discuss what glucagon receptor agonism can add to GIP/GLP-1 RAs. Next, Dr. Harpreet Bajaj (LMC Diabetes & Endocrinology, Canada) will excitedly present the full results of the phase 3 TRANSCENT-T2D-1 (n=537) trial of retatrutide in people with T2D. Topline results showed that retatrutide conferred 2% A1c reduction and 17% weight loss at Week 40. Lastly, Ania Jastreboff (Yale University) will present results from TRIUMPH-1 (n=2,300), the first phase 3 study of retatrutide in people with obesity. Dr. Alice Cheng (University of Toronto, Canada) will close the session with independent commentary.
• (1:30 pm – 3:00 pm): Session #1: What's new with CGM systems? This rapid-fire oral session features six talks exploring the expanding clinical role of CGM across diverse populations and care settings. To open, Dr. Jovan Milosavljevic (Albert Einstein College of Medicine) will examine the comparative effectiveness of CGM and GLP-1 RAs in primary care (1169-IR), while Dr. Tamara Oser (University of Colorado) will present findings from the CONNECT randomized trial evaluating CGM in adults with T2D not using insulin (1172-OR). Dr. Jennifer Layne (Dexcom) will assess the association between CGM use and cardiovascular outcomes (1171-OR), and Dr. Elena Toschi (Joslin Diabetes Center) will discuss how age-specific remote education can improve CGM adoption in older adults (1172-OR). Next, Dr. Francine Kaufman (Senseonics) will present long-term data on the implantable, one-year Eversense 365 CGM (1173-OR). Rounding out the session, Dr. Lalantha Leelarathna (Imperial College London, UK) will share subgroup analyses from the FReeDM2 trial, exploring CGM outcomes in patients using combination therapies for T2D (1174-OR).
• (1:30 pm – 3:00 pm): Preventing Type 2 Diabetes: Recent Advances. This oral presentation session chaired by Dr. J. Echouffo Tcheugui (Johns Hopkins University) will span a broad range of topics from COVID-19 treatment and diabetes to gene therapy. First, Dr. Bahareh Rasouli (Harvard University) will discuss the relationship between Paxlovid use and two-year diabetes risk, followed by a discussion of the risk of prediabetes progression stratified by antihyperglycemic drug class by Ms. Gabriela Siew (Johns Hopkins University). Next, Dr. Donald Simonson (Brigham and Women’s Hospital) will discuss diabetes remission after bariatric surgery versus lifestyle modification, and Ms. Vitoria Faiao (Helmholtz University, Germany) will provide an overview of clinical subphenotypes of T2D. Finally, Dr. Afif Nakhleh (Maccabi Healthcare Services, Israel) and Dr. Joan Sabadell-Basallote (Fractyl Health) will discuss individual care pathways for diabetes progression and gene therapy to enhance beta cell function.
• (3:15 pm – 4:15 pm): ADA statement on diabetes technology in primary care. Chaired by Dr. Eugene E. Wright, Jr. (South Piedmont AHEC), this symposium will provide practical guidance on integrating diabetes technology into primary care practice. Experts in the discussion include Dr. Sean Oser (University of Colorado Anschutz), Dr. Thomas Martens (Park Nicollet Clinic), and Dr. Osagie Ebekozien. The discussion will overview how CGM and insulin delivery devices are being used in primary care and strategies to promote technology implementation. The session draws from the ADA’s recently updated guidance on diabetes technology and aims to equip primary care providers with actionable tools for bringing device-based care into everyday clinical workflows.

Sunday, June 7

• (8:00 am – 9:30 am): The AIDING trial: Automated insulin delivery in the hospital — Results and implications for inpatient diabetes care. The full results of the AIDING trial will be presented during this morning symposium as presenters examine what they mean for the future of inpatient diabetes technology. The session will open with Dr. Georgia Davis (Emory University), who will outline the rationale for using diabetes technologies in the hospital and the potential role of AID systems in improving inpatient glycemic management. Dr. Michael Hughes (Emory University) will then discuss the operational considerations for implementing AID in acute care settings, including nursing workflows and systems integration. The main focus of the session will be Dr. Sue Brown’s (University of Virginia) presentation of the AIDING trial’s efficacy and safety data, followed by Dr. Francisco Pasquel’s (Emory University) contextualization of the findings within current inpatient protocols.
• (8:00 am – 9:30 am): Innovative approaches to weight management. This session, chaired by Dr. Jonathan Purnell (Oregon Health & Science University), will highlight the rapidly evolving landscape of treatments for obesity and T2D. Drs. Leili Gao (Peking University People’s Hospital) and Linong Ji (Peking University People’s Hospital) will share new trial results on Innovent Biologics’ mazdutide (oxyntomodulin; dual GLP-1/glucagon RA), which has been approved by China’s NMPA for obesity in June 2025 and for T2D in September 2025. Dr. Purnell will first present the results of the phase 3 GLORY-2 trial (n=462) for mazdutide treatment in adults with obesity. Following, Dr. Ji will discuss the phase 3b DREAMS-3 trial (n=349), which compares mazdutide directly against semaglutide in patients with both T2D and obesity. Dr. Mingtong Xu (Sun Yat-Sen Memorial Hospital) will present results from the REBUILDING-1 phase 2 trial (n=132) evaluating a biweekly GLP-1/GIP RA, RAY1225. Closing the session, Dr. Richard Nkulikiyinka (Antag Therapeutics) will share studies on the tolerability and pharmacodynamics of AT-7687, a once-weekly injectable GIP receptor antagonist.
• (9:45 am – 11:15 am): President, Medicine & Science Address and Banting Medal for Scientific Achievement Award Lecture. In this special lecture, Dr. Takashi Kadowaki (Toranomon Hospital, Japan) will receive the Banting Medal for Scientific Achievement. In his address, “What is Type 2 Diabetes? A Long Journey to Seek an Elusive Truth,” he will reflect on his career studying insulin action and resistance. Dr. Enrique Caballero (Harvard Medical School) will then deliver his President’s address, “From Mechanism to Milieu: Unifying Biomedical Science and Social Determinants in Diabetes Care,” highlighting his career as an endocrinologist and educator, and his long-standing commitment to health equity.
• (12:30 pm – 1:30 pm): What’s new in diabetes technologies? This afternoon’s session will highlight emerging applications of diabetes technology across inpatient care, high-risk populations, and novel data analytics. Dr. Sue Brown (University of Virginia) will present data on AID system use in hospitalized individuals receiving corticosteroids (1848-P), followed by Dr. Rohit Parab (Emory University), who will examine whether inpatient AID improves glycemic outcomes regardless of baseline A1c levels (1849-P). Together, their presentations provide additional evidence of the potential benefits of expanding AID use in acute care settings. Outside of the hospital, Dr. Katarzyna Cyranka (Jagiellonian University Medical College, Poland) will share results from the HI-LOOP study evaluating the metabolic and psychological benefits of the CamAPS FX hybrid closed-loop system in high-risk adults with T1D, elevated A1c, and concurrent mental health challenges (1850-P). The session will also look beyond traditional glycemic endpoints. Dr. Molly Tanenbaum (Stanford University) will present data from an international survey on Time in Tight Range (TITR), a metric that continues to gain traction among people with diabetes seeking even tighter glycemic targets (1900-P). Broader digital health applications will be featured in Dr. Pauli Ohukainen’s (Oura Health) analysis of wearable physiological signals and glucose biosensor data from 46,000 adults without self-reported diabetes (1901-P), while Dr. Tomoki Okuno (UCLA) will present data suggesting CGM metrics may predict substantial kidney function decline in adults with T1D and T2D (1902-P).
• (1:30 pm – 3:00 pm):Immune modulatory strategies for next-generation cell therapies. This symposium will explore emerging approaches to improving immune tolerance and long-term function of cell‑based therapies for diabetes. Dr. Jessica Weaver (Arizona State University) will begin with a presentation on a placental mimicry approach to induce tolerance toward insulin‑secreting cell therapies, followed by Dr. Jacqueline Burke (Northwestern) discussing immune-engineering strategies to promote islet graft tolerance. Dr. Paraish Misra (McGill University, Montreal, Canada) will then present work on HLA-edited pluripotent stem cells designed to evade T-cell, NK-cell, and antibody-mediated rejection. Dr. Piotr Witkowski (University of Chicago) will close with insights on anti‑CD40L based approaches to enhance graft survival and function in islet allotransplantation. We look forward to hearing how these complementary strategies may shape the next generation of immune‑protected cell therapies.
• (1:30 pm – 3:00 pm):The benefits of glucagon/GLP-1 receptor dual agonism: Insights from the phase 3 SYNCHRONIZE trials of survodutide. This session will highlight emerging science behind dual glucagon/GLP‑1 RAs and their therapeutic potential in obesity and metabolic disease, drawing from the phase 3 SYNCHRONIZE-1 trial. Dr. Matthias Tschöp (Ludwig Maximilian University of Munich, Germany) will open with an overview of gut hormone receptor poly‑agonists, covering their discovery and clinical validation. Dr. Ania Jastreboff (Yale University) will then outline the rationale and design of the SYNCHRONIZE phase 3 program for obesity treatment, followed by Dr. Carel le Roux (St. Vincent’s University Hospital & University College Dublin, Ireland), who will present efficacy and safety results from SYNCHRONIZE‑1 in people without diabetes. The session will conclude with Dr. Jaime Almandoz (UT Southwestern) discussing the clinical implications of dual glucagon/GLP‑1 RA activation for obesity and steatotic liver disease. We look forward to hearing how these complementary perspectives illuminate the practical considerations of next‑generation dual‑agonist therapies.
• (1:30 pm – 3:00 pm): Debate - Muscle Loss in GLP-1 Receptor Agonist–Induced Weight Loss: A Real Concern or Much Ado about Nothing? In this debate, Dr. Sam Klein (Washington University in St. Louis) and Dr. Eric Ravussin (Pennington Biomedical Research Center) will take opposing positions on the issue of muscle loss observed with GLP‑1 RAs. Dr. Klein will open by arguing that observed lean mass changes largely reflect appropriate metabolic adaptation during a negative energy balance. Dr. Ravussin will counter that even modest decrements in muscle quality and function may carry long‑term consequences for strength, mobility, and metabolic health. We also expect that this discussion will resonate strongly in light of emerging data from the phase 2 BELIEVE trial, where the combination of semaglutide and bimagrumab delivered deep weight reduction with high preservation of lean mass.
• (3:15 pm – 4:15 pm): Kelly West Award for Outstanding Achievement in Epidemiology Lecture. The Kelly West Award will be presented to Dr. Mohammed Ali (Emory University) this year in recognition of two decades at the forefront of national and global diabetes epidemiology. In his award lecture, “To Average or Not to Average: The Epidemiological and Translation Challenges of Precision Diabetes,” Dr. Ali will tackle the tension between population-level statistics and the precision needed to address individual cases.
• (3:15 pm – 4:15 pm): Session #2: What’s new with insulin delivery systems? This oral presentation session will highlight next-generation AID and bihormonal systems, particularly in specialized and high-risk populations. To open, Dr. Hans De Vries (Amsterdam University Medical Center, the Netherlands) will present results from the PANAROMA trial comparing a bihormonal AID system to current standard care in individuals who have undergone a total pancreatectomy (1257-OR). Next, Dr. Anders Carlson (International Diabetes Center) will share STRIVE trial data on a next-generation Omnipod algorithm in adults with T2D (1258-OR). Additional presentations will examine whether precise carbohydrate counting remains necessary for optimal AID performance, including Ms. Navya Basavaraju’s ( Shrewsbury and Telford Hospital NHS Trust, UK) pilot comparison of precise versus estimated carbohydrate counting (1259-OR) and Ms. Joelle Doumat’s (McGill University Health Center, Canada) randomized trial of a fully closed-loop insulin and pramlintide system versus traditional carbohydrate counting (1260-OR). Together, the session should offer compelling new trial data on how insulin delivery systems are becoming increasingly automated and reducing user burden.
• (4:30 pm – 6:00 pm) Getting along with your algorithm. This practical session will focus on how individuals and clinicians can optimize AID use across a range of real-world scenarios. The University of Colorado’s Dr. Gregory Forlenza will share general strategies for improving AID performance, and Dr. Sarit Polsky will discuss considerations for AID use during pregnancy, a population where glycemic targets remain especially complex. Finally, Stanford University’s Dr. Dessi Zaharieva will review recommendations for optimizing AID use during exercise, one of the most common and persistent challenges for users.

Monday, June 8

• (8:00 am – 9:30 am): GLP-1 receptor agonists: What's new in 2026? We’ll be up early on Monday to attend this comprehensive symposium, which promises to cover the latest developments in GLP-1 RAs. Dr. Donna Ryan (Pennington Biomedical) will offer a look at the latest in the obesity pipeline, including current clinical trials on incretin-based therapies. Next, Dr. Sean Wharton (University of Toronto, Canada) will discuss GLP-1 RAs for treating osteoarthritis with obesity medications. Finally, Dr. Ian Neeland (Case Western Reserve University) and Ms. Patti Urbanski (PBU Consulting, Minnesota) will share approaches to preserve lean body mass and optimal nutrition while using GLP-1 RA therapies, respectively.
• (8:00 am – 9:30 am): Joint ADA/ISPAD symposium: A global perspective on pediatric type 1 diabetes screening. This symposium will examine emerging global approaches to earlier identification of T1D in childhood and adolescence. Dr. Jean Claude Katte (University of Exeter Medical School, UK) will highlight inequities in islet autoantibody screening and explain why a one-size-fits-all strategy is not suitable for pediatric risk assessment. Dr. Holly O’Donnell (Barbara Davis Center) will follow with insights on the psychosocial dimensions of screening, exploring how families experience and navigate early‑risk information. Dr. Nicole Sheanon (Cincinnati Children’s Hospital Medical Center) will close with a session on clinical conundrums in monitoring children and adolescents who test positive for a single autoantibody. We are excited to see how these perspectives collectively inform a more equitable, evidence‑aligned, and family‑centered approach to T1D screening.
• (9:45 am – 11:15 am) National Scientific & Health Care Achievement Awards Presentation. This session brings together two of the ADA’s most prestigious recognition lectures. To start, Dr. Timo Müller (Helmholtz Munich, Germany) will deliver the Outstanding Scientific Achievement Award Lecture, “Hormonal Control of Metabolism by GIP and Next-Generation Incretin-based Polyagonists.” Next, Dr. Diana Isaacs (Cleveland Clinic) will deliver the Outstanding Educator in Diabetes Award Lecture, “Behind Every Number is a Story: Transforming Diabetes Care and Education Through Technology and Human Connection,” emphasizing the importance of translating clinical advances into real-world practice.
• (1:30 pm – 3:00 pm): Session #2: What's new with CGM systems? This afternoon session will highlight advances in both CGM hardware and data interpretation. Dr. Timothy Bailey (Headlands Research AMCR Institute) will present safety and efficacy data on a needle-free intradermal glucose sensor with integrated activity and sleep tracking (1295-OR). Next, Dr. Jacob Kohlenberg (University of Minnesota) will present his work associating CGM metrics with diabetic ketoacidosis risk (1296-OR). Presenting more on CGM metrics, Dr. Hadija Marchiori (University of Padua, Italy) will introduce a CGM-derived disposition index for stage 1 T1D (1298-OR). Dr. Ramzi Ajjan (Leeds Institute of Cardiovascular and Metabolic Medicine, UK) and Dr. Lalantha Leelarathna (Imperial College London, UK) will present data examining how updated glucose management indicator calculations may better align with laboratory A1c levels (1299-OR) and reduce the overdiagnosis of prediabetes (1297-OR). Finally, Dr. Bruce Bode (Atlanta Diabetes Associates) will present pediatric performance data on the iCan CGM system from a US multicenter study (1300-OR).
• (1:30 pm – 3:00 pm): From pen to pill: Achieving a paradigm shift in type 2 diabetes — The orforglipron 'ACHIEVE' clinical trial program.” In this symposium, the full results of the ACHIEVE-2, 3, and 5 trials evaluating oral GLP-1 RA orforglipron will be read out. As background, the topline results of these trials were announced in September and October 2025, demonstrating robust A1c reductions. Dr. Michelle Welch (Diabetes and Metabolism Specialists, Texas) will share full results from ACHIEVE-2 (n=888), which found that orforglipron conferred greater A1c reduction (-1.7% vs. -0.8%), compared to dapagliflozin in T2D. Dr. Julio Rosenstock (University of Texas Southwestern) will next discuss the ACHIEVE-3 (n=1,698) results, in which orforglipron led to greater A1c reduction (-2.2% vs. 1.4%) and weight loss (9.2% vs. 5.3%), compared to oral semaglutide in T2D. Prof. Francesco Giorgino (University of Bari Aldo Moro, Italy) will present results from ACHIEVE-5 (n=520), which showed that orforglipron further reduced A1c by 2.1%, compared to placebo (0.8%) when used as an add-on to titrated insulin glargine. Finally, Dr. Alice Cheng will close the session, exploring where nonpeptide oral GLP-1 RA fits in the treatment algorithm.
• (3:15 pm – 4:15 pm): Session #3: What's new with CGM systems? In another afternoon session on CGMs, several speakers will examine the growing role of the technology across the broader T2D population. Opening the session, Dr. Shivani Mehta (Abbott) will present data suggesting that FreeStyle Libre use may help individuals not on insulin therapy reach glycemic targets more quickly (1341-OR). Later, Dr. Thomas Martens (International Diabetes Center) will share findings from the GluCoCare study comparing CGM with BGM in insulin-treated adults managed in primary care (1343-OR). Dr. Richard Bergenstal (International Diabetes Center) will present retrospective analyses indicating that CGM metrics may provide guidance on insulin efsitora titration comparable to fasting blood glucose-based approaches, potentially simplifying weekly dose adjustments (1342-OR). The session will conclude with Dr. Jennifer Layne (Dexcom), who will report near- and long-term outcomes from more than 7,000 adults with T2D using Dexcom CGM.
• (3:15 pm – 4:15 pm): AZD5004, a novel oral small molecule GLP-1 receptor agonist: Overweight/obesity (VISTA) and type 2 diabetes (SOLSTICE) phase 2 trial results. In this session, speakers will present phase 2b data on AstraZeneca’s AZD5004, an investigational oral GLP‑1 RA being evaluated across obesity and T2D. Prof. Melanie Davies (University of Leicester, UK) will present results from the VISTA trial of AZD5004, assessing efficacy, safety, and tolerability in adults with obesity or overweight and comorbidities. Dr. Vanita Aroda (Brigham and Women’s Hospital) will follow with findings from the phase 2b SOLSTICE trial, evaluating AZD5004 in adults with T2D. The session will conclude with Dr. Klara Rachel Klein (University of North Carolina) providing independent commentary on the clinical implications of the therapy. In the 4Q25 call, AstraZeneca said that AZD5004 met its primary endpoints in both trials and that the company will advance the candidate into phase 3 this year. We are excited to hear about the therapeutic potential of AZD5004 and how it may further expand the growing list of oral GLP‑1 RAs.
• (3:15 pm – 4:15 pm): Precision medicine for new onset type 1 diabetes: interim phase 3 outcomes of retogatein (rhGAD65) antigen immunotherapy in DIAGNODE-3. This symposium will explore emerging precision‑medicine approaches for preserving endogenous insulin production in newly diagnosed T1D. Dr. Jason Gaglia (Joslin Diabetes Center) will open with a discussion of the clinical benefits of maintaining endogenous insulin. Dr. Johnny Ludvigsson (Linköping University) will then outline the design of the HLA‑guided phase 3 trial of Diamyd Medical’s retogatein (rhGAD65), highlighting how genetic stratification informs immunotherapy development. Dr. Tom Donner (Johns Hopkins University) will present 15‑month interim safety and efficacy results from the DIAGNODE‑3 trial. This follows recent interim findings from Diamyd indicating that the futility analysis showed no effect on C‑peptide and no identifiable responder subgroups, results described by company leadership as unexpected and prompting a comprehensive reassessment of trial procedures, immunologic data, and placebo‑group behavior. We are eager to hear how today’s presenters interpret these interim outcomes and what they may signal for the future of precision immunotherapy in new‑onset T1D.
• (3:15 pm – 4:15 pm): Debate - Immediate AI Integration into Health Care Delivery: Considering Costs, Quality, and Clinician Burnout. In this timely debate, Dr. Nestoras Mathioudakis (Johns Hopkins University) and Dr. Neda Laiteerapong (University of Chicago) will take opposing positions on whether AI should be integrated immediately into health care delivery or whether a more cautious “wait‑and‑see” approach is warranted. Dr. Mathioudakis will open by making a case for rapid adoption, emphasizing the potential for AI to enhance care quality and reduce clinician burden, while Dr. Laiteerapong will argue for a path that accounts for cost, equity, and real‑world readiness. We look forward to this session and hope it prompts thoughtful discussion on one of the most consequential questions facing modern clinical practice.

-- by Riya Chatterjee, Kayla Mathieu, Milenka Men, Elizabeth Rose, Jeremy Alkire, Katherine Moon, Monica Oxenreiter, and Kelly Close